Adam M. Weidner

Array ( [id] => 16466683 [patent_doc_number] => 20200368220 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-26 [patent_title] => Treatment of Aging-Associated Disease with Modulators of Leukotriene A4 Hydrolase [patent_app_type] => utility [patent_app_number] => 16/985780 [patent_app_country] => US [patent_app_date] => 2020-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31370 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16985780 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18413166 [patent_doc_number] => 11667699 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-06-06 [patent_title] => Anti-MS4A4A antibodies and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/943123 [patent_app_country] => US [patent_app_date] => 2020-07-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 50 [patent_figures_cnt] => 63 [patent_no_of_words] => 76299 [patent_no_of_claims] => 93 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16943123 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17850568 [patent_doc_number] => 20220280609 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => COMBINATION CANCER THERAPY AGENTS AND METHODS [patent_app_type] => utility [patent_app_number] => 17/625062 [patent_app_country] => US [patent_app_date] => 2020-07-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13190 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -63 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17625062 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16570660 [patent_doc_number] => 20210009666 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-14 [patent_title] => HUMANIZED TAU ANTIBODIES IN ALZHEIMER'S DISEASE [patent_app_type] => utility [patent_app_number] => 16/926062 [patent_app_country] => US [patent_app_date] => 2020-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67009 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16926062 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18003992 [patent_doc_number] => 20220362758 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-17 [patent_title] => ANTIBODY DRUG CONJUGATE PURIFICATION [patent_app_type] => utility [patent_app_number] => 17/623913 [patent_app_country] => US [patent_app_date] => 2020-07-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16720 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17623913 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16999501 [patent_doc_number] => 11078293 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-03 [patent_title] => Anti-human transferrin receptor antibody capable of penetrating blood-brain barrier [patent_app_type] => utility [patent_app_number] => 16/909398 [patent_app_country] => US [patent_app_date] => 2020-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 90925 [patent_no_of_claims] => 47 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16909398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16999501 [patent_doc_number] => 11078293 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-03 [patent_title] => Anti-human transferrin receptor antibody capable of penetrating blood-brain barrier [patent_app_type] => utility [patent_app_number] => 16/909398 [patent_app_country] => US [patent_app_date] => 2020-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 90925 [patent_no_of_claims] => 47 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16909398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16999501 [patent_doc_number] => 11078293 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-03 [patent_title] => Anti-human transferrin receptor antibody capable of penetrating blood-brain barrier [patent_app_type] => utility [patent_app_number] => 16/909398 [patent_app_country] => US [patent_app_date] => 2020-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 90925 [patent_no_of_claims] => 47 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16909398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16999501 [patent_doc_number] => 11078293 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-03 [patent_title] => Anti-human transferrin receptor antibody capable of penetrating blood-brain barrier [patent_app_type] => utility [patent_app_number] => 16/909398 [patent_app_country] => US [patent_app_date] => 2020-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 90925 [patent_no_of_claims] => 47 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 115 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16909398 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17635036 [patent_doc_number] => 11345749 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-05-31 [patent_title] => Humanized antibodies that recognize alpha-synuclein [patent_app_type] => utility [patent_app_number] => 16/903271 [patent_app_country] => US [patent_app_date] => 2020-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 6 [patent_no_of_words] => 13008 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16903271 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17844928 [patent_doc_number] => 11434281 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-06 [patent_title] => Monoclonal antibodies targeting PHF1 and AT8 epitopes of human tau protein [patent_app_type] => utility [patent_app_number] => 16/899307 [patent_app_country] => US [patent_app_date] => 2020-06-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 55 [patent_no_of_words] => 16656 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16899307 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16657421 [patent_doc_number] => 20210054057 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-02-25 [patent_title] => AGENTS, USES AND METHODS FOR THE TREATMENT OF SYNUCLEINOPATHY [patent_app_type] => utility [patent_app_number] => 16/895471 [patent_app_country] => US [patent_app_date] => 2020-06-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31662 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16895471 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17822691 [patent_doc_number] => 11427629 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-08-30 [patent_title] => Anti-Tau antibodies and methods of use [patent_app_type] => utility [patent_app_number] => 16/893678 [patent_app_country] => US [patent_app_date] => 2020-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 41 [patent_figures_cnt] => 56 [patent_no_of_words] => 39337 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 100 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16893678 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16557181 [patent_doc_number] => 20210002329 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-01-07 [patent_title] => STRUCTURE-BASED PEPTIDE INHIBITORS OF ALPHA-SYNUCLEIN AGGREGATION [patent_app_type] => utility [patent_app_number] => 16/883515 [patent_app_country] => US [patent_app_date] => 2020-05-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21549 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16883515 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16420614 [patent_doc_number] => 20200345812 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-05 [patent_title] => METHODS OF NEUROPROTECTION INVOLVING MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR AGONISTS [patent_app_type] => utility [patent_app_number] => 16/880431 [patent_app_country] => US [patent_app_date] => 2020-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16360 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16880431 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16452604 [patent_doc_number] => 20200362030 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => CAVEOLIN-1 ANTIBODY FOR USE IN TREATING BRAIN INFLAMMATION AND INJURY AND IMPROVING FUNCTIONAL RECOVERY [patent_app_type] => utility [patent_app_number] => 16/874019 [patent_app_country] => US [patent_app_date] => 2020-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7427 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16874019 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20757033 [patent_doc_number] => 12649792 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-06-09 [patent_title] => Bispecific antibodies against CHI3L1 and PD1 with enhanced T cell-mediated cytotoxic effects on tumor cells [patent_app_type] => utility [patent_app_number] => 17/609309 [patent_app_country] => US [patent_app_date] => 2020-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 25913 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 205 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17609309 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16883769 [patent_doc_number] => 20210169964 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-06-10 [patent_title] => METHODS OF TREATING ALZHEIMER'S DISEASE, HUNTINGTON'S DISEASE, AUTISM, AND OTHER DISORDERS [patent_app_type] => utility [patent_app_number] => 16/867324 [patent_app_country] => US [patent_app_date] => 2020-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5989 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -6 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16867324 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16451041 [patent_doc_number] => 20200360467 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-19 [patent_title] => TARGETING G3BP PROTEINS TO ACCELERATE NERVE REGENERATION [patent_app_type] => utility [patent_app_number] => 16/857636 [patent_app_country] => US [patent_app_date] => 2020-04-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10837 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16857636 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18070518 [patent_doc_number] => 11529334 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-20 [patent_title] => Pharmaceutical composition for treating or preventing Parkinson's disease comprising STT as an active ingredient [patent_app_type] => utility [patent_app_number] => 16/852182 [patent_app_country] => US [patent_app_date] => 2020-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 20 [patent_no_of_words] => 6446 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16852182 [rel_patent_id] =>[rel_patent_doc_number] =>)